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Kidney Transplantation Under FK 506 Immunosuppression 
R. Shapiro. M. Jordan. J. Fung. J. McCauley, J. Johnston. Y. Iwaki. A. Tzakis. T. Hakala. S. Todo. 
and T.E. Starzl 
WE RECENTLY reported our initial experience with FK 506 in 36 patients undergoing renal transplan-
tation. 1 This series was characterized by a high average 
complexity. and included 10 patients who also were liver 
recipients either concomitantly or at an earlier time. Ad-
ditionally, 2 of the 10 also were given a heart or pancreas. 
We report here a follow-up of the 26 patients from that 
original expenence who were pure kidney recipients. plus 
39 more treated through June 3. 1990. The first pure renal 
recipient underwent her third cadaveric transplantation on 
April 14. 1989. She was highly sensitized (panel reactive 
antibody [PRA) 93%) and rejected the graft. The next 
effort. also a retransplantalJon. was made on September 
13. 1989. This was successful. Consequently. the follow-up 
to be reported of surviving grafts is 2.5 to II months. 
METHODS 
The 65 patients were given a total of 66 grafts. all cadaveric except 
for 2 (father to daughter. sister to sisterl. Of the tnlnsplantations. 
43 (65.2%) were primary. The other 23 (34.8%1 were transplanted 
in patients who were receiving their second to fourth grafts. one 
secondary recipient being a failure from the pnmary series (Table 
I). The mean recipient age was 39.9 := 13.5 (SOl years. with 10 
paUents over the age of 55. Diabetes mellitus was the cause of 
renal failure in 19 of 65 (29.2%) recipients and glomerulonephritis 
was the cause in 13 (20%) patients. Several patients undergoing 
retransplantation often had the diagnosis of chronic rejeCllon 
and/or cyclosponne (CyAI toxicity (Table 21. 
Good HLA matches were uncommon. In 49 of 66 (74.2%) 
transplantallons. only 0 to 2 of the 0 possible antigens were 
matched: 12 C18.2%) were performed with 3 antigen matches and 
5 (7.6%1 with 4. The mismatches reflected a generallv similar 
histolncompauble pattern. With the mismatch assessment there 
were only 3 (4.5%1. I (1.5%1. and!! (12.I'7CI examplesofO. I. and 
~ antigen mismatches, respecuvelv. 
Thirty of 65 (46.1%) pattents w'ere considered to be presensi-
tized In that their dithiothreitol COrn-treated; current or stored 
sera contained antibodies against 11'7c to 98% of the 62 donors 
who contributed to the PRA screening tray: the PRA was >40% in 
Table 1. Ca .. Material 
CadavenC: Living-Aelated Total 
Reoplents 63 2 65 
Grafts 64 2 66· 
1 st 42 1 43 (65.2%1 
2nd 17 0 17 (25.8%) 
3rd 4 1 5 (7.6%) 
4th 0 1 (1.5%) 
Note. Mean reallNllll age was 39.9 ~ , 3.5 years. InCIUIIIng IIIe only pedlalnC 
r8QClllllll WIIO was 10 ye ... Old. 
. One DBIIenI ned a tllSl and seoona c:acsawnc altograll dunng this bme penod 
(ApnlI4. 198910 June 3. '9901. 
Table 2. Cau ... of Renal Failure 
Diabetes mellitus 
Glomerutoneptmtls 
HypenenslOn 
ChroniC relectlon/ CyA damage 
PolycystiC kidney disease 
Systemic lupus erythematosis 
Focal segmental glomerulosclerosis 
ChroniC reJectiOn 
Hemolytic-uremic syndrome 
IgA nephropathy 
Sickle cell disease 
Renal cell carcinoma 
Medullary cystic disease 
Congenital hypoplaSia 
Interstitial nephntls 
Total 
Numberf%) 
19 (29.2) 
13(20.0) 
7 (10.8) 
5 (7.7) 
5 (7.7) 
4 (6.2) 
3(4.6) 
2 (3.1) 
1 (1.5) 
1 (1.5) 
1 (1.5) 
1 (1.5) 
1 (1.5) 
1 (1.5) 
1 (1.5) 
65 
19.7%. In 6 (9.1%) of the patients. transplantation was performed 
across a weakly or unequivocaily positive cytotoxic crossmatch 
using current or stored sera or both. 
The mean cold ischemia time for the 64 cadaveric kidnevs was 
35.9 ~ 9.8 hours. Fony-four(66.7%) of the organs were rec~vered 
elsewhere and sent to Pittsburgh. Pediatric en bloc kidneys from 
donors <3 years of age were used in 16 cases (24.2%). The oldest 
cadaveric kidney was from a 65-year-old donor. The mean donor 
age was 33.2 := 16.4 years for the 50 kidneys which were not en 
bloc. 
FK 506 and corticosteroids were used in all patients. The initial 
dose of 0.075 or 0.15 mg/kg FK 506 was usuallv started IV in the 
recoverv room 2 hours after transplantation and given over 2 to 4 
hours. In a few senslllzed pattents. FK 506 was begun mtraoper-
atively. Further IV doses of 0.075 mg/kg were given every 12 
hours until the patient could tolerate oral FK 506. which was 
begun at a dose of O.IS mglkg tWice per day. In recent cases (not 
included herellV FK 506 has been given as a continuous infusion 
of 0.10 or 0.15 mglkg over 24 hours. Trough plasma FK 506 levels 
were measured using the method of Tamura et al.·\ 
The first 25 patients received a 1000 mg bolus of IV methyl-
From the Department of Surgery. University Health Center 01 
Pittsburgh. UniverSity of Pittsburgh. and lhe Veterans Administra-
tion Medical Center. Pittsburgh. PennsylVania. 
Supponed by research gra'llts from the Veterans Administration 
and project grant no. OK 29961 from the National Institutes of 
Health. Bethesda. MD. 
Address repnnt requests to Thomas E. Starz!. MD. PhD. De-
partment of Surgery. 3601 Fifth Ave. Falk CliniC. Pittsburgh. PA 
15213. 
c) 1991 by Appleton & Lange 
0041·13451911$3.00/+0 
920 TraJISl)IBntBtIOII ProceedIngS. 1101 23. No 1 (February). 1991: pp 920-923 
FK 506 IMMUNOSUPPRESSION 
prednisolone dunng the operation. followed by an attenuating 
predmsone burst which decreased from 200 mg to 20 m[!ld over 6 
days. The subsequent 40 patients were ltlven 20 mgld of pred· 
nisone from the outset. When possible. the sterOId dose was 
tapered over the first several weeks and stopped. Supplementary 
steroids or OKT3 were given if rejection was suspected clinically 
or diagnosed with biopsy. 
RESULTS 
Graft Function and Survival 
Forty-one of the 66 (62.1%) kidneys functioned immedi-
ately. while 25 07.9%) had some form of delayed graft 
function. presumably from acute tubular necrosis (ATN). 
All but two of the A TN group required dialysis for at least 
I week after transplantation. with the longest delay being 
over I month before recovery. Three more grafts have 
good flow with radionuclide scanning but are not function-
ing well enough to stop dialysis (Table 3). and are classed 
as failures in this analysis. 
Fifty-two of the 65 (80.0%) patients are free of dialysis 
With a mean creatinine of 2.2 :!: 1.2 (So) mg/dL and blood 
urea nitrogen (BUN) of 37 :!: 25 mg/dL. Kidney survival is 
34 of 43 (79.1%) of primary grafts vs 18 of23 (78.3%) after 
retransplantation (Table 3). Graft survival is 83.3% in the 
nonsensitized patients vs 73.3% in those who had pre-
formed cytotoxic antibodies. 
Rejection was the most frequent cause of graft loss 
(Table 3). The rate of this final diagnosis was about equal 
with primary grafting vs retransplantation (Table 3). How-
ever. the sensitized patients who were heavily represented 
in the retransplant group had irreversible rejection at three 
times the rate of patients without cytotoxic antibodies. 
particularly if there was a cytotoxic crossmatch (Table 3). 
The imbalance is even greater if the diagnosis is assumed 
to be rejection in the three patients with continuing dys-
functional grafts: two of the three were presensitized. 
Re.iectJon accounted for the loss of only three primary 
grafts with a negative crossmatch. one in a patient who 
also had sickle cell crises in the postoperative penod. The 
other losses were in diabetic women. One. who lost her 
graft in 10 days. underwent successful retransplantatlon 5 
Table 3. Graft Survival and cau ... of Graft Loa. 
Primaly Retransplan- k~· s-tlzed 
34143' tabOn 18123 tiled 30136 22130 
Graft SulYivai (79.1%) (78.3%) (83.3%) 173.3%) 
Graf1IOSS 9/43 5/23 6136 8J3O 
(20.9%) (21.7%) (16.7%) (26.7%) 
Rejection 5 3 2 6 
ConbnUing 
dysfunction 2 2 
Necrobc donor 
renal anery 
MycolIC 
pseuooaneurysm 
Death 
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months later. The second woman lost her graft after an 
unwise decision was made to reduce FK 506 by half 5 
months postoperatively. She had a perfect result at the 
time. and was not on steroids. 
Two of the graft losses in primary nonsensitized recipi· 
ents were due to donor disease which was not recognized. 
In one. the aortic conduit for en bloc pediatric kidneys was 
found later to have had transmural necrosis pretransplan-
tation. and clotted in less than 24 hours. A delayed 
peritoneal culture from another en bloc pediatric donor 
showed mixed bacteria. The recipient of the liver from this 
donor developed severe candida peritonitis within 72 
hours. The kidney recipient developed a candida mycotic 
pseudoaneurysm. necessitating removal of the normally 
functioning graft and ligation of the iliac artery 32 days 
postoperatively. Recipient death accounted for the other 
primary graft loss after 2 days in a nonsensitized recipient. 
If these three nonimmunologic failures are excluded from 
the analysis. the graft loss rate in primary transplantation 
is 6 of 40 (15%) and in the nonsensitized recipients. it is 3 
of 33 (9.1%). 
Immunosuppressive ReqUirement 
During most of the time of this pilot case compilation. the 
treatment protocol was not standardized. A 3- to 5-day 
course of 5 or 10 mg/d OKT3 was given after 18 of 66 
(27.3%) transplantations. However. the reasons for this 
decision in preference to FK 506 or steroid augmentation 
were variable and sometimes not biopsy validated. Aza-
thioprine maintenance therapy was never used. Conse-
quently. the best judgment about the efficacy of FK 506 
was based on how much prednisone was required to 
maintain stable graft function after the first 2 months. This 
information is given in Table 4 after follow-ups of 2.5 to 11 
months. Of the 52 (80.0%) patients of the original 65 who 
have functioning grafts. 31 (59.6%) did not receive ste-
roids. 8 (J5.4%) more were on 2.5·5 mgld. and 12 (23.1%) 
were taking 10-20 mgld. One patient (1.9%) is taking 25 
mg/d. 
Infections 
These are reported elsewhere at this meeting by Kusne et 
al. 4 The infectious profile was similar to that with past 
immunosuppressive regimens. However. lethal systemic 
sepsis was notably absent. possibly because of the limited 
use of steroids. Cytomegalovirus (CMV) was the most 
common infection and 8 of the 65 patients had clinical 
problems serious enough to be treated with Ganciclovir. 
Table 4. Steroid Requirement. In 52' Patient. With Functioning 
Grafts (2.5 to 11 Momn.) 
Prednisone Dose 
o 
2.5·5 mgJd 
10-20 mgJd 
25 mgJd 
No. of Patients ("10) 
31 (59.6) 
8 (15.4) 
12 (23." 
1 (1.9) 
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Table 5. Antihypertensive Medications In 52 Patients With 
Functioning Grafts 
No. of MedICa\JOl1S 
o 
1 
2 
3 
Late Postoperative Risk Factors 
No. of Pabents (%) 
21 (40.4) 
24 (46.21 
5 (9.6) 
2 (3.8) 
Even in successful cases. renal transplant recipients his-
torically have had a high incidence of complications which 
may impact negatively on the quality of life or the long-
term prognosis. These were examined in the 52 patients 
who have functioning grafts. 
Hypertension. Most of the patients who came to trans-
plantation were taking antihypertensive medications. At 
present. 45 (86.6%) are free of these medications or on 
monodrug therapy (Table 5). 
Hvperchole.fferolemia and H\'peruricemiu. The serum 
cholesterol for the 52 patients is 172 = 38 mgldL (SOl 
(lower range of normal) and the mean uric acid levels are 
7.8 = 2.2 mgldL (SOl (high range of normall. 
New Diabetes Mellitus. Five of 52 (9.6%) patients with 
surviving grafts were not diabetic before transplantation. 
but needed chronic insulin therapy afterwards. This inci-
dence is comparable to or lower than that reported for 
conventional immunosuppressive regimens. $.7 
Neurotoxicity. Central and peripheral nervous system 
toxicity was evaluated systematically with the use of a 
questionnaire that was designed to elicit complaints of 
tremors. insomnia. headaches. light sensitivity. night-
mares. hallucinations. tingling. and more serious manifes-
tations such as convulsions or paralysis. The most com-
mon side effects were tremors. paresthesias of the hands 
and/or feet. and insomnia. These tended to be relatively 
minor and most patients did not spontaneously complain. 
Serious neurologic problems such as the expressive dys-
phasia which we reported in two liver reclpientsM were not 
seen. 
DISCUSSION 
These trials with renal transplantation came late and 
played a relatively minor role in the clinical introduction of 
FK 506 therapy which concerned mainlv the Iiver.9- 11 
However. the kidney trials have added to 'the impression 
that this is a safe drug to the extent that safety is possible 
with any powerful immunosuppressant. The mortality in 
the present trial was 1.5%. and the freedom from historical 
posttransplant morbidity was impreSSIve. This was due 
largely to the ability to minimize or stop steroids within the 
first 2 months in 75% of cases. None of the kidney or 
nearly 500 other organ recipients treated with FK 506 was 
ever switched to another drug. 
In earlier publications. we delineated the principal side 
effects of FK 506 as nephrotoxicity. neurotoxicity. and 
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diabetogenicity. 12·14 Nephrotoxicity is not easy to define in 
the renal transplant model. but precise studies in heart and 
liver recipients are being reported. f~ It appears that the 
greatest risk of nephrotoxicity is during the early postop-
erative period when there IS a tendency toward overdosage 
and consequent high blood levels while the drug is given 
IV. I" Undoubtedly. improvements will be possible during 
this so-called induction. Afterwards. minor oral dose ad-
justments are easy to make. more or less guided by plasma 
trough levels. The supreme confounding factor in dose 
control is hepatic dysfunction.lt-.n The absence of severe 
hypertension. or the relief of this condition when it had 
predated transplantation is noteworthy. 
The diabetogenic effects of FK 506 therapy have been 
similar to those seen in past regimens. Like Cy A. FK 506 
inhibits insulin release by pancreatic islets and it may 
increase peripheral insulin resistance. III 
Similarly. neurotoxicity. while important to assess. fol-
lows the same general pattern as CyA. So far. serious 
neurotoxicity has been noted only in liver reclpients.H This 
is not surprising since pathologic demyelinating changes in 
the brain stem caused bv end-stage liver disease involve 
the same general anatomic regions as may be demyelinated 
by drugs like FK 506 and CyA. 
As discussed elsewhere. 19 it is more than coincidence 
that both the desired qualities and side effects of FK 506 
and CyA follow a similar pattern. in which the expression 
of details may be significantly different. However. hyper-
cholesterolemia. hyperuricemia. and hypertension. which 
have been troublesome features of Cy A regimens.2o are 
not prominent features of FK 506. Whether this advantage 
is also related primarily to low steroid needs will be 
determined with further observations. 
Comparisons of the therapeutic efficacy as well as the 
toxicity of FK 506 vs Cy A undoubtedly will be clarified in 
the randomized trials that are now proceeding with hepatic 
and renal transplantation. At the moment. FK 506 appears 
to be the superior drug. 
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